Price to Book Value (P/BV)
since 2005
Paying user area
Try for free
Pfizer Inc. pages available for free this week:
- Analysis of Solvency Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Common Stock Valuation Ratios
- Net Profit Margin since 2005
- Return on Equity (ROE) since 2005
- Return on Assets (ROA) since 2005
- Total Asset Turnover since 2005
- Price to Earnings (P/E) since 2005
- Price to Sales (P/S) since 2005
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Pfizer Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Pfizer Inc., P/BV, long-term trends, calculation
| P/BV | = | Share price1, 2, 3 | ÷ | Book value per share1 (BVPS) | BVPS1 | = | Total Pfizer Inc. shareholders’ equity1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2025 | = | ÷ | = | ÷ | |||||||
| Feb 22, 2024 | = | ÷ | = | ÷ | |||||||
| Feb 23, 2023 | = | ÷ | = | ÷ | |||||||
| Feb 24, 2022 | = | ÷ | = | ÷ | |||||||
| Feb 25, 2021 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2020 | = | ÷ | = | ÷ | |||||||
| Feb 28, 2019 | = | ÷ | = | ÷ | |||||||
| Feb 22, 2018 | = | ÷ | = | ÷ | |||||||
| Feb 23, 2017 | = | ÷ | = | ÷ | |||||||
| Feb 29, 2016 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2015 | = | ÷ | = | ÷ | |||||||
| Feb 28, 2014 | = | ÷ | = | ÷ | |||||||
| Feb 28, 2013 | = | ÷ | = | ÷ | |||||||
| Feb 28, 2012 | = | ÷ | = | ÷ | |||||||
| Feb 28, 2011 | = | ÷ | = | ÷ | |||||||
| Feb 26, 2010 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2009 | = | ÷ | = | ÷ | |||||||
| Feb 29, 2008 | = | ÷ | = | ÷ | |||||||
| Mar 1, 2007 | = | ÷ | = | ÷ | |||||||
| Mar 1, 2006 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Pfizer Inc. Annual Report.
The price-to-book value (P/BV) ratio exhibited considerable fluctuation over the observed period, spanning from 2006 to 2026. Initial values indicated a P/BV around 2.94, which decreased through 2009 to a low of 1.44 before beginning a period of moderate increase.
- Initial Decline and Recovery (2006-2011)
- From 2006 to 2007, the P/BV ratio decreased from 2.94 to 2.49. A further decline was observed through 2009, reaching 1.44, potentially reflecting market conditions during that period. Subsequently, the ratio experienced a recovery, increasing to 1.75 by 2011, though it remained below the initial value from 2006.
- Moderate Fluctuations (2012-2016)
- The period between 2012 and 2016 saw moderate fluctuations in the P/BV ratio. It rose to 1.95 in 2012 and 2.42 in 2013, then peaked at 2.95 in 2014 before decreasing slightly to 2.84 in 2016. This suggests a period of relative stability with some volatility.
- Peak and Subsequent Decline (2017-2024)
- A notable peak in the P/BV ratio occurred in 2019, reaching 3.80. This was followed by a decline to 3.00 in 2020, and a slight decrease to 2.98 in 2021. A more substantial decline was then observed, falling to 2.48 in 2022 and further to 1.75 in 2023. This trend continued into 2024, with the ratio reaching 1.68.
- Recent Stabilization (2025-2026)
- The most recent two years, 2025 and 2026, show a slight stabilization, with the P/BV ratio increasing to 1.78 and 1.78 respectively. This suggests a potential leveling off after the previous decline, though it remains at a lower level than observed in the late 2010s.
Overall, the P/BV ratio demonstrates sensitivity to market dynamics and company-specific factors. The significant decline from 2019 to 2024 warrants further investigation to determine the underlying causes, while the recent stabilization may indicate a potential bottoming out of the ratio.
Comparison to Competitors
Pfizer Inc., P/BV, long-term trends, comparison to competitors
| Pfizer Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | ||||||||||||
| Feb 27, 2025 | ||||||||||||
| Feb 22, 2024 | ||||||||||||
| Feb 23, 2023 | ||||||||||||
| Feb 24, 2022 | ||||||||||||
| Feb 25, 2021 | ||||||||||||
| Feb 27, 2020 | ||||||||||||
| Feb 28, 2019 | ||||||||||||
| Feb 22, 2018 | ||||||||||||
| Feb 23, 2017 | ||||||||||||
| Feb 29, 2016 | ||||||||||||
| Feb 27, 2015 | ||||||||||||
| Feb 28, 2014 | ||||||||||||
| Feb 28, 2013 | ||||||||||||
| Feb 28, 2012 | ||||||||||||
| Feb 28, 2011 | ||||||||||||
| Feb 26, 2010 | ||||||||||||
| Feb 27, 2009 | ||||||||||||
| Feb 29, 2008 | ||||||||||||
| Mar 1, 2007 | ||||||||||||
| Mar 1, 2006 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Pfizer Inc., P/BV, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Pfizer Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 26, 2026 | ||
| Feb 27, 2025 | ||
| Feb 22, 2024 | ||
| Feb 23, 2023 | ||
| Feb 24, 2022 | ||
| Feb 25, 2021 | ||
| Feb 27, 2020 | ||
| Feb 28, 2019 | ||
| Feb 22, 2018 | ||
| Feb 23, 2017 | ||
| Feb 29, 2016 | ||
| Feb 27, 2015 | ||
| Feb 28, 2014 | ||
| Feb 28, 2013 | ||
| Feb 28, 2012 | ||
| Feb 28, 2011 | ||
| Feb 26, 2010 | ||
| Feb 27, 2009 | ||
| Feb 29, 2008 | ||
| Mar 1, 2007 | ||
| Mar 1, 2006 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Pfizer Inc., P/BV, long-term trends, comparison to industry (health care)
| Pfizer Inc. | Health Care | |
|---|---|---|
| Feb 26, 2026 | ||
| Feb 27, 2025 | ||
| Feb 22, 2024 | ||
| Feb 23, 2023 | ||
| Feb 24, 2022 | ||
| Feb 25, 2021 | ||
| Feb 27, 2020 | ||
| Feb 28, 2019 | ||
| Feb 22, 2018 | ||
| Feb 23, 2017 | ||
| Feb 29, 2016 | ||
| Feb 27, 2015 | ||
| Feb 28, 2014 | ||
| Feb 28, 2013 | ||
| Feb 28, 2012 | ||
| Feb 28, 2011 | ||
| Feb 26, 2010 | ||
| Feb 27, 2009 | ||
| Feb 29, 2008 | ||
| Mar 1, 2007 | ||
| Mar 1, 2006 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).